In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011

Executive Summary

Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.

You may also be interested in...



Will A Dividend Keep Investors Happy As Amgen Waits For Its Pipeline To Pan Out?

Amgen outlines its strategic priorities through 2016, but analysts and investors seem more concerned with near-term initiatives that could pan out before year's end.

Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab

Amgen Inc. is going through a transformational time as many of its top-selling drugs are maturing and its latest potential blockbuster franchise tries to find a foothold in the market. While Prolia/Xgeva (denosumab) offers a lucrative lifeline for the big biotech, investors are getting anxious about the company’s future; pushing for a dividend and for clarity about its strategy.

Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?

Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel